Royal Gold, Inc. Share Price Target ‘$151.58’, now 16.2% Upside Potential

DirectorsTalk Interviews

Royal Gold, Inc. which can be found using ticker (RGLD) have now 12 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The target price High/Low ranges between $167.00 and $129.00 calculating the mean target share price we have $151.58. (at the time of writing). Now with the previous closing price of $130.45 this indicates there is a potential upside of 16.2%. The 50 day moving average now sits at $121.82 while the 200 day moving average is $114.77. The market capitalization for the company is 8.46B. The stock price is currently at: $128.68 USD

The potential market cap would be $9,828,629,528 based on the market consensus.

The company has a dividend yield of 0.55%. Other points of data to note are a P/E ratio of 38.07, revenue per share of $9.84 and a 7.44% return on assets.

Royal Gold, Inc. is a precious metals stream and royalty company. The Company is engaged in the acquisition and management of precious metal streams, royalties, and similar production-based interests. The Company operates through two segments: Acquisition and Management of Stream Interests, and Acquisition and Management of Royalty Interests. The Company owns royalty interests on approximately 32 production stage properties, 18 development stage properties and on approximately 123 exploration stage properties. It owns a portfolio of producing, development, evaluation, and exploration stage streams and royalties on properties located in gold regions. The Company’s principal properties include Andacollo, Cortez, Khoemacau Project, Mount Milligan, Penasquito and Pueblo Viejo.

Share on:
Find more news, interviews, share price & company profile here for:

    Drax confirms final HEIT offer and plans to let scheme lapse

    Drax Group plc updates on its acquisition offer for HEIT, confirming a final bid of 88p per share while announcing potential changes to the acquisition timeline.

    Poolbeg Pharma raises £4.7m through Placing and Subscription

    Poolbeg Pharma has successfully raised £4.715 million to fund innovative clinical trials, including POLB 001 and an oral GLP-1 programme, addressing critical medical needs.

    DynaResource technical report validates 250000oz of gold and significant upside

    DynaResource, Inc. unveils a promising S-K 1300 Technical Report for the San Jose de Gracia mine, revealing 250,000 gold ounces in Initial Mineral Reserves.

    Vodafone Group Plc launches €500m Share Buyback

    Vodafone Group Plc announces a €500 million share repurchase program aimed at reducing share capital, set to commence on May 20, 2025.

    Warpaint London posts 2024 Annual Report and AGM Notice

    Warpaint London plc (LON:W7L) announces the release of its 2024 Annual Report and details for the upcoming AGM on June 17, 2025.

    Poolbeg Pharma launches £4.1m fundraising

    Poolbeg Pharma plc (LON:POLB) announces a conditional fundraising aimed at raising £4.1 million to drive innovative pharmaceutical developments and address unmet medical needs.

      Search

      Search